Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma

Gynecologic Oncology

Volumn 92, Issue 1, 2004, Pages 175-179

  Mayerhofer, Klaus ^a   Lozanov, Plamen ^a   Bodner, Klaus ^a   Bodner Adler, Barbara ^a   Obermair, Andreas ^a   Kimberger, Oliver ^a   Czerwenka, Klaus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ki 67; Prognosis; Uterine leiomyosarcoma; VEGF

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; PARAFFIN; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BIOSYNTHESIS; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; METABOLISM; MORTALITY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL; SURVIVAL RATE; UTERUS CANCER; UTERUS LEIOMYOSARCOMA; UTERUS TUMOR;

EID: 0742324880     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.10.028     Document Type: Article

References (31)

1. Norris H.J., Zaloudek C.J. Mesenchymal tumors of the uterus. Kuman R.J., Blaustein A. Pathology of the female genital tract. Second ed. 1982;352-392 Springer Verlag, New York.
2. Zaloudek C., Norris H.J. Mesenchymal tumors of the uterus. Kuman R.J., Blaustein A. Pathology of the female genital tract. Fourth ed. 1994;487-528 Springer Verlag, New York.
3. Bell S.W., Kempson R.L., Hendrickson M.R. Problematic uterine smooth muscle neoplasms. A clinopathological study of 213 cases. Am. J. Surg. Pathol. 18(6):1994;535-558.
4. Evans H.L., Chawla S.P., Simpson C., Finn K.P. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer. 62:1988;2239-2247.
5. Nola M., Babic D., Ilic J., Marusic M., Uzarevic B., Petrovecki M.et al. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus. Cancer. 78:1996;2543-2550.
6. Larson B., Silfverswärd C., Nilsson B., Pettersson F. Prognostic factors in uterine leiomyosarcoma. A clinical and histopathological study of 143 cases. The radiumhemmet series 1936-1981. Acta Oncol. 29:1990;185-192.
7. Kahanpää K.V., Wahlström T., Gröhn P., Heinonen E., Nieminen U., Widholm O. Sarcomas of the uterus. A clinicopathologic study of 119 patients. Obstet. Gynecol. 67:1986;417-424.
8. Van Dinh T., Woodruff J.D. Leiomyosarcoma of the uterus. Am. J. Obstet. Gynecol. 144:1982;817-823.
9. Mayerhofer K., Obermair A., Windbichler G., Petru E., Kaider A., Helfer L.et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol. Oncol. 74(2):1999;196-201.
10. Mineta H., Miura K., Ogino T., Takebayashi S., Misawa K., Ueda Y. Vascular endothelial growth factor (VEGF) expression correlates with p-53 and Ki-67 expressions in tongue squamous cell carcinoma. Anticancer Res. 22(2B):2002;1039-1044.
11. Xie B., Tam N.N., Tsao S.W., Wong Y.C. Co-expression of vascular endothelial growth factor VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat. Br. J. Cancer. 81(8):1999;1335-1343.
12. Cattoretti G., Becker M.H., Key G., Duchrow M., Schluter C., Galle J.et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave processed formalin-fixed paraffin sections. J. Pathol. 168:1992;357-363.
13. Layfield L.J., Liu K., Dodge R., Barsky S.H. Uterine smooth muscle tumors: Utility of classification by proliferation, ploidity, and prognostic markers versus traditional histopathology. Arch. Pathol. Lab. Med. 124:2000;221-227.
14. Mittal K., Demopoulos R.I. MIB-1 (Ki-67), p-53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum. Pathol. 32(9):2001;984-987.
15. Chou C.Y., Huang S.C., Tsai Y.C., Hsu K.F., Huang K.E. Uterine Leiomyosarcoma has deregulated cell proliferation, but not increased microvessel density compared with uterine leiomyoma. Gynecol. Oncol. 65:1997;225-231.
16. Zhai Y.L., Kobayashi Y., Mori A., Orii A., Nikaido T., Konishi I.et al. Expression of steroid receptors, Ki-67, and p-53 in uterine leiomyosarcomas. Int. J. Gynecol Pathol. 18:1999;20-28.
17. Jeffers M.D., Oakes S.J., Richmond J.A., Macaulay E.M. Proliferation, ploidity and prognosis in uterine smooth muscle tumors. Histopathology. 29:1996;217-223.
18. Zhai Y.L., Nikaido T., Shizawa T., Orii A., Fujii S. Expressions of cyclins and cyclin-dependent kinases in smooth muscle tumors of the uterus. Int. J. Cancer. 84:1999;244-250.
19. Amada S., Nakano H., Tsuneyoshi M. Leiomyosarcoma vs. bizarre and cellular leiomyomas of the uterus: A comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p-53 expression, DNA flow cytometry, and muscle specific actins. Int. J. Gynecol. Pathol. 14:1995;134-142.
20. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:1992;989-991.
21. Boocock C.A., Charnock-Jones D.S., Sharkey A.M., McLaren J., Barker P.J., Wright K.A.et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J. Nat. Cancer Inst. 87:1995;506-516.
22. Masood R., Cai J., Zheng T., Smith D.L., Naidu Y., Gill P.S. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc. Acad. Sci. 94:1997;979-984.
23. de Jong J.S., van Diest P.J., van de Valk P., Baak J.P. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J. Pathol. 184:1998;44-52.
24. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
25. Seshadri R., Leong A.S., McCaul K., Firgaira F.A., Setlur V., Horsfall D.J. Relationship between p53 gene abnormalities and other tumor characteristics in breast cancer prognosis. Int. J. Cancer. 69:1996;135-141.
26. Rudolph P., Olsson H., Bonatz G., Ratjen V., Bolte H., Baldetorp B.et al. Correlation between p53, c-erb B-2, and topoisomerase IIa expression, DNA plodity, hormonal receptor status and proliferation in 356 node negative breast carcinomas: prognostic implications. J. Pathol. 187:1999;207-216.
27. Dunton C.J., van Hoeven K.H., Kovatich A.J., Oliver R.E., Scacheri R.Q., Cater J.R.et al. Ki-67 antigen staining as an adjunct to identifying cervical intraepithelial neoplasia. Gynecol. Oncol. 64:1997;451-455.
28. Geisler J.P., Geisler H.E., Miller G.A., Wiemann M.C., Zhou Z., Crabtree W. MIB-1 in endometrial carcinoma: Prognostic Significance with 5-year follow-up. Gynecol. Oncol. 75:1999;432-436.
29. Mirza A.N., Mirza N.Q., Vlastos G., Singletary S.E. Prognostic factors in dnode-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann. Surg. 235:2002;10-26.
30. Dong P., Sakata K., Miyajima Y., Chijiwa K., Mori K., Nakashima T. The predictive value of p53, and Ki-67 and angiogenetic factors in primary hypopharyngeal carcinoma. Kurume Med. 48(4):2001;261-266.
31. Emoto M., Iwasaki H., Ishiguro M., Kikuchi M., Horiuchi S., Saito T.et al. Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and the expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. Human Pathol. 30(10):1999;1232-1241.